Patents by Inventor George R. Siber

George R. Siber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10406220
    Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naive adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: September 10, 2019
    Assignee: Wyeth LLC
    Inventors: George Rainer Siber, Peter R. Paradiso, Jill Hackell, Stephen Paul Lockhart, William P. Hausdorff
  • Publication number: 20180369365
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Application
    Filed: January 3, 2018
    Publication date: December 27, 2018
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Patent number: 9895436
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 20, 2018
    Assignee: Genocea Biosciences, Inc.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Publication number: 20140227307
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Application
    Filed: November 12, 2013
    Publication date: August 14, 2014
    Applicant: GENOCEA BIOSCIENCES, INC.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Patent number: 8617564
    Abstract: Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: December 31, 2013
    Assignee: Genocea Biosciences, Inc.
    Inventors: Deborah Long, Jessica Flechtner, Mojca Skoberne, George R. Siber
  • Patent number: 7892563
    Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: February 22, 2011
    Assignee: Wyeth Holdings Corporation
    Inventor: George R. Siber
  • Patent number: 7722886
    Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: May 25, 2010
    Assignee: Wyeth
    Inventor: George R. Siber
  • Publication number: 20040235047
    Abstract: Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
    Type: Application
    Filed: May 20, 2003
    Publication date: November 25, 2004
    Inventor: George R. Siber
  • Patent number: 6384188
    Abstract: Substance which bind with high affinity to endotoxin (lipopolysaccharide [LPS]), and which are useful for the prevention or treatment of, for example, Gram-negative and Gram-positive bacterial sepsis, and for the treatment of bacterial and fungal infections as well as for neutralizing effects associated with heparin. The substances are LPS-binding peptides comprising an LPS-binding domain. DNA sequences encoding peptides, recombinant microorganisms containing the DNA, pharmaceutical compositions containing the peptides of the invention, and diagnostic kits. Methods for the detection and removal of bacterial LPS from solutions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 7, 2002
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adolf Hoess, Robert C. Liddington, George R. Siber
  • Patent number: 5582827
    Abstract: A process for identifying plasma samples containing effective antibody titers for the treatment and/or prophylaxis of infections caused by a respiratory virus. The process comprises contacting a plasma sample containing antibodies against a respiratory virus with the respiratory virus. The mixture of plasma sample and virus is then contacted with a plurality of cells. The remaining non-neutralized virus in the sample is then determined through an immunoassay following replication of the virus in the cells. Plasma samples which, at a preselected minimum antibody titer value, prevent viral replication in the cells, are then selected. Plasma from which the selected samples were derived are then pooled to provide an immunoglobulin preparation having increased effectiveness in the prophylaxis and/or treatment of infections caused by the respiratory virus.
    Type: Grant
    Filed: January 27, 1995
    Date of Patent: December 10, 1996
    Assignee: Massachusetts Health Research Institute, Inc.
    Inventors: George R. Siber, Jeanne Leszczynski
  • Patent number: 5412077
    Abstract: A process for identifying plasma samples containing effective antibody titers for the treatment and/or prophylaxis of infections caused by a respiratory virus. The process comprises contacting a plasma sample containing antibodies against a respiratory virus with the respiratory virus. The mixture of plasma sample and virus is then contacted with a plurality of cells. The remaining non-neutralized virus in the sample is then determined through an immunoassay following replication of the virus in the cells. Plasma samples which, at a preselected minimum antibody titer value, prevent viral replication in the cells, are then selected. Plasma from which the selected samples were derived are then pooled to provide an immunoglobulin preparation having increased effectiveness in the prophylaxis and/or treatment of infections caused by the respiratory virus.
    Type: Grant
    Filed: August 4, 1993
    Date of Patent: May 2, 1995
    Assignee: Massachusetts Health Research Institute, Inc.
    Inventors: George R. Siber, Jeanne Leszczynski
  • Patent number: 4310508
    Abstract: A highly sensitive direct particle agglutination test capable of routinely detecting as little as 0.2 nanograms of antigen per milliliter of clinical fluid and characterized by uniform sensitivity as well as stability is disclosed as well as coated particles having a sensitivity of 0.2 nanograms antigen per milliliter and methods for preparing such coated particles. In addition, a method to reduce the frequency of non-specific agglutination with human sera to 2% or less is described.
    Type: Grant
    Filed: June 19, 1979
    Date of Patent: January 12, 1982
    Inventor: George R. Siber